- Home
- AMAL vs CGEM Comparison
AMAL vs CGEM Comparison
Compare AMAL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | CGEM |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 873.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMAL | CGEM |
|---|---|---|
| Price | $41.89 | $14.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $36.00 | $30.11 |
| AVG Volume (30 Days) | 112.8K | ★ 720.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | $5.20 |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.13 | $5.68 |
| 52 Week High | $42.66 | $16.74 |
Technical Indicators
Market Signals| Indicator | AMAL | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 69.34 | 52.30 |
| Support Level | $36.56 | $11.43 |
| Resistance Level | $42.66 | $16.74 |
| Average True Range (ATR) | 0.84 | 0.91 |
| MACD | 0.37 | 0.03 |
| Stochastic Oscillator | 90.86 | 57.10 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.